The Second Meeting of the Europe Regional Chapter of the US Pharmacopeial Convention (USP), held on April 30, 2024, in Basel, Switzerland, marked a significant event for stakeholders in the pharmaceutical sector. Organized by USP EMEA, this meeting brought together experts from pharmacopoeias, regulatory bodies, academic institutions, and industry organizations to foster ongoing collaboration and shape USP's strategic initiatives for 2025-2030.
The meeting featured valuable insights from speakers representing renowned organizations, including EDQM, MHRA, Ukrainian Scientific Pharmacopoeial Center for Quality of Medicines, PEI, TITCK, Medicines for Europe, A3P, APIC, IEIS, and Istanbul University. Dr Natalia Volovyk, Deputy Director for Quality at the Ukrainian Scientific Pharmacopoeial Center for Quality of Medicines, presented on the topic of "Introduction to National Monographs of the State Pharmacopoeia of Ukraine – Seeking Ways to Cooperate." She highlighted the center's achievements in metrological support for the quality of analysis results, validation of analytical procedures, and certification of reference standards, and proposed ways for further partnerships between Ukraine and other international entities. The discussions covered critical topics such as enhancing pharmaceutical supply chains, broadening access to biologics, improving health outcomes, and advancing environmental sustainability in pharmaceutical manufacturing.
FIP CEO Catherine Duggan, who chaired the event, emphasized the importance of these discussions in promoting access to quality medicines and fostering regulatory innovation. USP Convention President Dennis Doherty contributed to the event, reinforcing the commitment to these shared goals.
The USP Europe Convention Second Regional Chapter Meeting successfully set the stage for future collaboration, recruitment of expert volunteers, and the alignment of efforts to ensure the continued promotion of quality medicines worldwide. The event underscored the collective dedication to improving global health outcomes through cooperation and innovation in the pharmaceutical sector.
Looking ahead, USP and its members are poised to build on the success of this meeting, driving forward initiatives that will have a lasting impact on the quality and accessibility of medicines globally.
